Search

Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune checkpoint blocker avelumab (Bavencio®) and the tyrosine kinase inhibitor (TKI) axitinib (Inlyta®) can significantly improve progression-free survival (PFS) in people who have been previously untreated for advanced renal cell carcinoma (RCC).

… Sunday, October 21, 2018 Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology ’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune

Learn how MSK's world-class Head and Neck cancer specialists help people facing throat cancer, using the latest therapies and innovations.

… Thursday, September 4, 2025 Throat cancer is a form of head and neck cancer. It starts in the throat (known as the pharynx), which includes the tonsils, back of the tongue, voice box (larynx), and the vocal cords. Some of these areas can be seen when the mouth is wide open and others only by a camera

New MSK research uncovers unique genetic signatures in cancer patients of non-European ancestry; identifies social adversity as a potential risk factor for higher rates of triple-negative breast cancer among Black women; shows a web-based system could help head-and-neck cancer survivors report their concerns; and finds adding immunotherapy can boost the effectiveness for hard-to-treat follicular lymphomas.

… Friday, October 31, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) uncovers unique genetic signatures in cancer patients of non-European ancestry; identifies social adversity as a potential risk factor for higher rates of triple-negative breast cancer among Black women; shows a web-based

MSK researchers continued to make strides against cancer in 2025. Learn about some of their top discoveries.

… Monday, December 15, 2025 Researchers at Memorial Sloan Kettering Cancer Center (MSK) continued to make strides against cancer in 2025. Laboratory research teams across the institution worked to advance the understanding of cancer cells and to develop new therapies, while also making fundamental insights

Cancer pain is common, even after treatment has ended, so doctors at MSK have developed a number of ways to treat cancer pain and help people get back to their lives. 

… Wednesday, September 25, 2024 Many people with cancer expect that their lives will go back to normal once their treatment has ended. That’s not always the case, unfortunately. There can be complex issues surrounding cancer survivorship , from the psychological impact of diagnosis and treatment — even

El dolor por cáncer es común, incluso después de que el tratamiento haya finalizado, por lo que los médicos de MSK han desarrollado una serie de métodos para tratar el dolor por cáncer y ayudar a las personas a retomar sus vidas. 

… Wednesday, September 25, 2024 Muchas personas con cáncer esperan que sus vidas vuelvan a la normalidad una vez que termine su tratamiento. Desafortunadamente, ese no es siempre el caso. Puede haber problemas complejos en torno a la sobrevivencia al cáncer , desde el impacto psicológico del diagnóstico

Learn how a stem cell-derived treatment shows potential for treating Parkinson's disease.

… Wednesday, April 16, 2025 A stem cell–based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson’s disease, according to results from a phase 1 clinical trial reported in Nature . The treatment involved creating nerve cells (neurons

Sentinel lymph node (SLN) mapping leads to significantly less lower-extremity lymphedema compared to comprehensive lymphadenectomy (LND) after hysterectomy in patients with endometrial cancer.

… Thursday, January 30, 2020 Sentinel lymph node (SLN) mapping leads to significantly less lower-extremity lymphedema compared to comprehensive lymphadenectomy (LND) after hysterectomy in patients with endometrial cancer, according to our research published recently in the journal Gynecology Oncology .

The 2016 annual meeting of the American Association for Cancer Research (AACR) ended with a visit from the Vice President.

… Thursday, April 21, 2016 Summary Continuing his work on the National Cancer Moonshot Initiative, Vice President Biden paid a visit to the annual meeting of the American Association for Cancer Research, where he highlighted his goals for cancer research in the coming years and what it will take to get

Topics included more diverse representation in clinical trials, racial disparities in colorectal cancer, and ancestry testing to improve diagnoses.

… Wednesday, April 13, 2022 Among the topics discussed at this year’s annual meeting of the American Association for Cancer Research (AACR) was disparities in cancer care. Several MSK researchers presented research that directly addresses these problems. In a prerecorded presentation, MSK physician-scientist